Animal experiments as a model for clinical trials of a new dosage form of mitomycin C for peritoneal carcinomatosis.
Rabbits with peritoneal carcinomatosis induced by VX2 carcinoma were used as an experimental model to study a new dosage form of mitomycin C, MMC-CH, comprising activated carbon adsorbing mitomycin C. Rabbits revived an intraperitoneal injection of mitomycin C (1 mg/kg in the form of MMC-CH or 0.185 mg/kg in the form of mitomycin C solution). The two doses were equal in toxicity. MMC-CH extended survival time measured in days to 139% as compared to mitomycin C solution. Autopsy findings showed peritoneal carcinomatosis to be much less developed with MMC-CH than with mitomycin C solution. Hematological and blood biochemical analyses showed no remarkable abnormality.
Hagiwara
A
A
Department of Surgery, Red Cross Hospital of Maizuri, Kyoto, Japan.
Takahashi
T
T
Lee
R
R
Ueda
T
T
Takeda
M
M
Itoh
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002244:Carbon; D002277:Carcinoma / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D016685:Mitomycin / Q000627:therapeutic use* / Q000633:toxicity; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011817:Rabbits
D000970:Antineoplastic Agents; D016685:Mitomycin; D002244:Carbon